Why capillary electrophoresis still matters in modern biopharma by Roxana McCloskey | Jun 9, 2026 | Biopharma, Blogs, CEExplore why capillary electrophoresis remains essential for high resolution, confident analytics across modern biopharma modalities, from proteins to mRNA and gene therapies
Where does capillary electrophoresis fit across drug development? by Roxana McCloskey | Jun 9, 2026 | Biopharma, Blogs, CECapillary electrophoresis (CE) is not confined to a single point in the drug development lifecycle. Its value comes from the ability to deliver high‑resolution, reproducible separations that remain relevant as analytical questions evolve, from early discovery through late‑stage development and lot release.
Introducing the SCIEX resource hub: All your resources, one place by Susanna Baqué | May 27, 2026 | Blogs, Support, Technology, TrainingFinding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
Why middle‑down and subunit MS analyses powered by EAD are transforming biopharmaceutical characterization by Roxana McCloskey | May 15, 2026 | Biopharma, BlogsAs an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
Why electron-activated dissociation (EAD) improves sequence variant analysis in biopharma LC/MS workflows by Roxana McCloskey | Apr 29, 2026 | Biopharma, BlogsIn biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
How NFD improves impurity detection and peak integration in CE SDS workflows by Roxana McCloskey | Apr 28, 2026 | Biopharma, BioPhase 8800 system, BlogsCE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
What´s new in SCIEX Now – spring release 2026 by Andrea Mueller | Apr 23, 2026 | Blogs, Service, Support, TrainingAt SCIEX, innovation doesn’t stop at instruments; it extends to how you interact with your LC-MS/MS or CE systems every day. That’s why we’re excited to introduce the SCIEX Now spring 2026 improvements: a set of meaningful enhancements shaped directly by your feedback.
The troubleshooting tool LC-MS users have been waiting for by Anja Pfenninger | Apr 23, 2026 | Blogs, Service, Support, TrainingIn today’s fast-paced analytical laboratories, uptime is not just important; it is mission-critical. Whether you are running high-throughput bioanalysis, environmental testing, or pharmaceutical workflows, every minute of LC-MS downtime can impact productivity, data quality, and timelines. That is why we are excited to introduce a smarter and faster way to troubleshoot.
Getting PFAS right: Why sample preparation matters by Sam Lodge | Apr 17, 2026 | Blogs, Environmental / Industrial, Food / BeverageUltra‑low reporting limits, expanding target lists, and the constant risk of background contamination mean that even small missteps before injection can compromise data integrity. PFAS can be introduced at nearly every stage of prep, from sampling containers and PPE to SPE cartridges, filters, solvents, and lab consumables, making contamination control as critical as analyte recovery.
CE‑SDS in monoclonal antibody therapeutic development by Roxana McCloskey | Mar 31, 2026 | Biopharma, BioPhase 8800 system, BlogsIn monoclonal antibody (mAb) development, assessment of purity and integrity of the protein in question is critical. CE‑SDS is the gold standard assay and is routinely run from analytical development through QC and lot release. It’s trusted because it consistently delivers quantitative, size‑based insight into purity and fragmentation, and it fits naturally into regulated environments.